Summary: Could currently available immunomodulatory therapies modify disability trajectories in patients with moderately advanced and advanced multiple sclerosis (MS)? Tomas Kalincik, Department of Medicine, University of Melbourne, Australia, discusses the findings from the MSbase cohort study with Elizabeth Highton. <p>Read the full article here: http://jnnp.bmj.com/content/88/3/196.</p>
